MGB Biopharma commences Phase I clinical trial with oral formulation of MGB-BP-3 for treatment of multi-resistant Clostridium Difficile infections

23-Jul-2015 - MGB Biopharma announced that the first group of healthy male volunteers have been dosed in a Phase I clinical trial assessing the safety and tolerability of an oral formulation of MGB-BP-3, for use in the treatment of Clostridium difficile infections.MGB-BP-3 is an antibiotic that has been shown ...

MGB Biopharma Nominated and Shortlisted for Scottish Enterprise Life Sciences Award

03-Dec-2014 - MGB Biopharma announced that it has been nominated and shortlisted for the 2015 Scottish Enterprise Life Sciences Annual Award for “Investment of the Year”. The awards, for which there are six categories this year, recognise excellence in companies and individuals who are making a significant ...

MGB Biopharma Receives £1.3m Grant Award

Grant to help fund Phase I trial with lead candidate oral MGB-BP-3 for Clostridium difficile

13-Jun-2014 - MGB Biopharma, a biopharmaceutical company developing truly novel anti-infectives, announced that it has been awarded a £1.3 million conditional grant from the Technology Strategy Board, the UK’s innovation agency, under its Biomedical Catalyst programme. The grant will help fund a Phase I trial ...